Inmode (INMD) Stock Price
Inmode Price
Over the last 9 years Inmode grew revenue by 36.1% annually, reaching 370.50 M USD. Earnings per share have grown at 37.5% per year over the last 8 years. For Inmode, the net margin of 25.3% is down versus 46.1% a few years ago. The consensus 12-month price target for Inmode is 16.32 USD, about 10.0% above where the stock trades today. Of 14 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 16% above its 52-week low.
Inmode stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Inmode over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Inmode stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Inmode's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Inmode Price |
|---|---|
| 9/3/2026 | 14.84 USD |
| 9/2/2026 | 14.95 USD |
| 9/1/2026 | 15.03 USD |
| 8/31/2026 | 14.96 USD |
| 8/30/2026 | 14.88 USD |
| 8/28/2026 | 14.85 USD |
| 8/27/2026 | 14.90 USD |
| 8/26/2026 | 14.93 USD |
| 8/25/2026 | 15.03 USD |
| 8/24/2026 | 15.06 USD |
| 8/21/2026 | 15.06 USD |
| 8/20/2026 | 14.92 USD |
| 8/19/2026 | 15.01 USD |
| 8/18/2026 | 14.97 USD |
| 8/14/2026 | 15.15 USD |
| 8/13/2026 | 15.20 USD |
| 8/12/2026 | 15.18 USD |
| 8/10/2026 | 15.19 USD |
| 8/7/2026 | 15.31 USD |
| 8/6/2026 | 15.12 USD |
| 8/5/2026 | 15.18 USD |
| 8/4/2026 | 15.27 USD |
| 8/3/2026 | 15.35 USD |
| 7/31/2026 | 15.14 USD |
| 7/30/2026 | 15.10 USD |
| 7/29/2026 | 15.12 USD |
| 7/27/2026 | 15.49 USD |
| 7/23/2026 | 15.09 USD |
| 7/22/2026 | 15.20 USD |
| 7/21/2026 | 15.36 USD |
Inmode Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Inmode Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.00 | 53.00 | 100.00 | 156.00 | 206.00 | 357.00 | 454.00 | 492.00 | 394.00 | 370.00 | 370.00 | 377.00 | 388.00 |
| – | 130.43 | 88.68 | 56.00 | 32.05 | 73.30 | 27.17 | 8.37 | -19.92 | -6.09 | – | 1.89 | 2.92 |
| 73.91 | 83.02 | 85.00 | 87.18 | 84.95 | 84.87 | 83.70 | 83.54 | 80.46 | 78.38 | 78.38 | 78.38 | 78.38 |
| 17.00 | 44.00 | 85.00 | 136.00 | 175.00 | 303.00 | 380.00 | 411.00 | 317.00 | 290.00 | 290.00 | 295.49 | 304.11 |
| – | 8.00 | 23.00 | 59.00 | 72.00 | 167.00 | 197.00 | 195.00 | 112.00 | 85.00 | 92.00 | 88.00 | 93.00 |
| – | 15.09 | 23.00 | 37.82 | 34.95 | 46.78 | 43.39 | 39.63 | 28.43 | 22.97 | 24.86 | 23.34 | 23.97 |
| – | 8.00 | 22.00 | 61.00 | 75.00 | 164.00 | 161.00 | 197.00 | 181.00 | 93.00 | 82.00 | 86.00 | 91.00 |
| – | – | 175.00 | 177.27 | 22.95 | 118.67 | -1.83 | 22.36 | -8.12 | -48.62 | -11.83 | 4.88 | 5.81 |
| 64.08 | 76.85 | 63.95 | 83.28 | 84.78 | 86.38 | 86.35 | 85.84 | 72.79 | 64.08 | 64.08 | 64.08 | 64.08 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Inmode generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Inmode retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Inmode's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Inmode has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Inmode's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Inmode stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Inmode Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Inmode business model & stock analysis
Inmode SWOT Analysis
Strengths
1. Innovation-driven: Inmode Ltd is known for its continuous innovation in the medical aesthetics industry, offering advanced technologies and treatment options.
2. Strong product portfolio: The company has a diverse range of high-quality products and solutions, including minimally invasive and non-invasive treatments, which cater to various customer needs.
3. Established brand: Inmode Ltd has built a solid reputation and brand presence in the market, gaining trust and recognition from both healthcare professionals and patients.
Weaknesses
1. Dependence on key markets: Inmode Ltd heavily relies on specific geographic regions, which may expose the company to market-specific risks and fluctuations.
2. Limited global reach: While the company has expanded its presence internationally, it still has room for further expansion to tap into untapped markets and increase market share.
3. Intense competition: Inmode Ltd faces fierce competition from other established players and emerging companies in the medical aesthetics sector. Maintaining and expanding market share can be challenging.
Opportunities
1. Growing demand for non-invasive treatments: The increasing preference for non-surgical aesthetic procedures presents an opportunity for Inmode Ltd to further expand its product offerings and capture a larger market share.
2. Rising consumer awareness: As consumer awareness about the benefits of aesthetic treatments increases, there is a potential for Inmode Ltd to educate and attract more customers, driving demand for its products.
3. Technological advancements: By staying at the forefront of technological advancements, Inmode Ltd can continue to develop and introduce innovative solutions, strengthening its competitive position in the market.
Threats
1. Regulatory challenges: Government regulations and guidelines related to medical devices and aesthetic treatments can pose challenges and impact the market potential of Inmode Ltd.
2. Economic downturns: In times of economic uncertainty or recessions, consumers may reduce their discretionary spending on aesthetic treatments, leading to a potential decline in demand for Inmode Ltd's products.
3. Counterfeit products and unauthorized distributors: The presence of counterfeit products and unauthorized distributors can harm Inmode Ltd's brand reputation and result in revenue losses.
Inmode Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Inmode Segments
Inmode Revenue by Segment
Max
Details
Inmode Revenue by Region
3 Years
Max
Details
Inmode Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Inmode historical P/E ratio, EBIT multiple, and P/S ratio
Inmode annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Inmode shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Inmode stock splits
Current Inmode forecasts and price targets in September 2026
Analyst Price Targets 2026Inmode Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 5/7/2026 | Maintained | Overweight | 57 | |
| 5/7/2026 | Maintained | Neutral | 62 | |
| 12/17/2025 | Maintained | Hold | 64 | |
| 11/6/2025 | Maintained | Neutral | 46 | |
| 10/10/2025 | Maintained | Hold | 70 | |
| 10/10/2025 | Maintained | Hold | 64 | |
| 7/30/2025 | Maintained | Hold | 70 | |
| 7/30/2025 | Maintained | Overweight | 57 | |
| 7/11/2025 | Maintained | Hold | 64 | |
| 4/30/2025 | Maintained | Overweight | 57 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Inmode Earnings Calls
Inmode Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/5/2026 | 0.34USD | - | 94.89 MUSD | - | 2026 Q2 |
| 5/6/2026 | 0.30USD | - | 81.80 MUSD | - | 2026 Q1 |
| 2/10/2026 | 0.43USD | - | 106.49 MUSD | - | 2025 Q4 |
| 4/30/2024 | 0.54USD | - | 113.92 MUSD | - | 2024 Q1 |
| 2/12/2024 | 0.70USD | - | 141.71 MUSD | - | 2023 Q4 |
| 7/26/2023 | 0.68USD | - | 136.72 MUSD | - | 2023 Q2 |
| 5/1/2023 | 0.46USD | - | 104.59 MUSD | - | 2023 Q1 |
| 2/8/2023 | 0.67USD | - | 131.62 MUSD | - | 2022 Q4 |
| 10/27/2022 | 0.60USD | - | 115.09 MUSD | - | 2022 Q3 |
| 7/28/2022 | 0.52USD | - | 104.68 MUSD | - | 2022 Q2 |
Inmode shareholder structure
| % | Name |
|---|---|
5.52277% | |
4.91598% | |
4.84127% | |
4.47985% | |
4.09799% | |
4.09281% |
Inmode Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
16.20% | SEC ↗ | |
13.53% | SEC ↗ | |
13.53% | SEC ↗ | |
13.53% | SEC ↗ | |
7.90% | SEC ↗ | |
5.11% | SEC ↗ | |
3.20% | SEC ↗ | |
1.00% | SEC ↗ | |
1.00% | SEC ↗ | |
1.00% | SEC ↗ |
Inmode Executives and Management Board
8 members · avg. age 64 · 25 % women
Mr. Michael Dennison (45)
President, North America
2.00 M USD
Management
Mr. Yair Malca (48)
Chief Financial Officer
Dr. Michael Kreindel (59)
Chief Technology Officer, Director · since 2008
Mr. Moshe Mizrahy (73)
Chief Executive Officer · since 2008
Ms. Miri Segal-Scharia
CEO - MS IR LLC
Board of Directors
Dr. Michael Anghel (87)
Independent Chairman of the Board
Mr. Nadav Kenneth (66)
Independent Director
Dr. Hadar Ron (67)
Independent Director
Inmode Supply Chain
Inmode Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.50 | 0.65 | 0.60 |
Frequently asked questions about Inmode
The business model of Inmode Ltd revolves around providing innovative medical aesthetics solutions. Inmode Ltd develops and markets advanced, minimally-invasive technologies used in aesthetic and surgical procedures. Their cutting-edge platforms, such as BodyTite, FaceTite, and Morpheus8, offer solutions for skin tightening, body contouring, facial rejuvenation, and cellulite reduction. Inmode Ltd's business model centers on combining radiofrequency technology with other modalities to deliver safe, efficient, and customizable treatments for both medical professionals and patients. By continuously developing and enhancing their product portfolio, they aim to meet the growing demands of the global aesthetic market and cater to the evolving needs of healthcare practitioners.
Inmode Ltd is primarily active in the aesthetic medical device industry.
The main competitors of Inmode Ltd in the market include companies such as Cutera Inc., Cynosure Inc., Alma Lasers Ltd., and Lumenis Ltd. These companies offer similar products and services in the medical aesthetics industry, which Inmode operates in. With its innovative technologies and strong market presence, Inmode competes with these industry players to gain a larger market share and maintain its position as a leading provider of aesthetic solutions.
Inmode Ltd is a leading global provider of innovative energy-based medical aesthetic solutions. Established in 2008, the company has rapidly grown to become a trusted name in the industry. Inmode's cutting-edge technology focuses on radiofrequency-based devices, enabling physicians to deliver effective aesthetic treatments with precision and optimal patient satisfaction. Inmode Ltd is headquartered in Israel but operates worldwide, serving thousands of medical professionals and patients alike. With a commitment to continuously expanding its portfolio and investing in research and development, Inmode Ltd remains at the forefront of the medical aesthetics field, dedicated to enhancing the lives of individuals through advanced and safe technology.
Inmode Ltd, a leading provider of medical aesthetic systems, has achieved several significant milestones. The company has successfully pioneered advanced technology in minimally invasive and non-invasive procedures for aesthetic treatments. Inmode Ltd has gained worldwide recognition for its innovative platform, which includes advanced radiofrequency, laser, and pulsed light technologies. With a strong focus on research and development, they have introduced cutting-edge solutions that address a wide range of aesthetic concerns effectively and safely. Inmode Ltd continues to revolutionize the field of medical aesthetics, solidifying its position as a market leader and providing patients with exceptional treatment options.
Inmode Ltd is primarily present in various countries and regions worldwide. The company's presence extends to the United States, where it has a significant market presence. In addition, Inmode Ltd has established a strong presence in Europe, including key markets such as Germany, France, Italy, and the United Kingdom. The company also operates in the Asia-Pacific region, with a focus on countries like China and Japan. With its global reach, Inmode Ltd continues to expand its presence and deliver innovative solutions in the field of aesthetic medical technology.
Inmode Ltd represents a strong set of core values and a corporate philosophy that distinguishes the company. With a focus on innovation and cutting-edge technology, Inmode aims to provide transformative solutions in the aesthetic and medical markets. The company prides itself on quality, reliability, and versatility, ensuring that customers can trust their products and services. Inmode's commitment to research and development enables them to deliver advanced solutions, empowering healthcare professionals to enhance patient care and achieve optimal results. By prioritizing customer satisfaction and continuous improvement, Inmode Ltd strives to remain a leader in the industry.
Analysts currently set an average price target of 17.14 USD for the Inmode stock (median: 16.32 USD), implying +14.9 % versus the latest price. The consensus is based on 14 analyst ratings.
14 analysts currently rate the Inmode stock: 7 recommend buying, 7 holding and 0 selling. For 2026, analysts expect Inmode to generate revenue of 370.32 M USD and earnings per share of 1.28 USD.
Converted at the current exchange rate, the Inmode share trades at 12.78 EUR (14.84 USD).
The Inmode share (INMD) is listed on 4 stock exchanges, including: NASDAQ (INMD), Frankfurt (154.F), München (154.MU), Düsseldorf (154.DU).
Inmode Ltd is a leading company in the medical technology industry, specializing in the development and commercialization of innovative aesthetic solutions. The company offers a wide range of products and services aimed at providing patients with fast, safe, and effective treatment for aesthetic problems. Inmode specializes in four main areas: body contouring and fat reduction, skin tightening, wrinkle reduction and skin rejuvenation, and common skin problems. To address these areas, the company has developed various advanced technologies and devices available to doctors and clinics. These include: - BodyTite: A revolutionary technology that uses radiofrequency energy to melt tissue, leading to effective body contouring with minimal invasiveness. - FaceTite: A technology based on the same principles as BodyTite but specifically developed for the face and neck to tighten loose skin and reduce wrinkles. - Morpheus8: A combination of micro-needles and radiofrequency energy that stimulates collagen production and tightens the skin, reducing wrinkles and unevenness. - Votiva: A device specifically designed for women that tightens the vagina and improves sexual health. These areas and products aim to cover the entire spectrum of aesthetic needs in order to build a successful and growing customer base. Inmode also has a unique business model that goes beyond traditional sales efforts. The company has developed a strong online presence that provides potential customers with everything they need to know about the company's products and services. Inmode has also built close relationships with medical professionals around the world to ensure that their products and technologies meet the highest medical standards. In addition to providing advanced medical devices to doctors and clinics, Inmode has also developed comprehensive training and support programs to ensure that doctors and clinics are trained in the use of their technologies and can achieve the best possible results for their patients. This business model has contributed to the company's growth and success in recent years, becoming a key factor in the aesthetic medicine industry. Overall, Inmode's business model demonstrates how innovative technologies and high-quality products and services, combined with online marketing and customer relationships, can lead to a successful company.
The expected revenue of Inmode is 370.32 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Inmode is 82.11 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Inmode is currently 11.58. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Inmode stock.
The price-to-sales ratio (P/S) of Inmode is currently 2.57. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Inmode stock.
The Eulerpool Quality Score for Inmode is 3/10.
The ISIN of Inmode is IL0011595993. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Inmode is A2PP3A. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Inmode is INMD. The ticker symbol is used to trade Inmode shares on the stock exchange.
Inmode paid dividends every year for the past 0 years.
Inmode is assigned to the 'Health' sector.
The dividends of Inmode are distributed in USD.
Inmode stock
Inmode Ticker
Inmode FIGI
All fundamentals and in-depth analysis of Inmode
Our stock analysis for Inmode stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inmode. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.